Literature DB >> 17704125

Quality of life evolution after surgery for primary or secondary spontaneous pneumothorax: a prospective study comparing different surgical techniques.

Bram Balduyck1, Jeroen Hendriks, Patrick Lauwers, Paul Van Schil.   

Abstract

The objective of the present study is to evaluate quality of life (QoL) evolution after video-assisted thoracic surgery (VATS) and anterolateral thoracotomy (AT) for primary and secondary spontaneous pneumothorax, which has not been studied prospectively until now. From January 2003 to December 2004, QoL was prospectively recorded in 20 consecutive patients, using the European Organisation for Research and Treatment of Cancer (EORTC) QoL Questionnaire-C30 and the lung specific module LC-13. Questionnaires were administered before surgery and 1, 3, 6 and 12 months postoperatively (MPO) with response rates of 100%, 85%, 80%, 65% and 60%, respectively. In this prospective, non-randomized study, all patients had wedge resection and apical pleurectomy, 45% by video-assisted thoracic surgery (VATS), and 55% by anterolateral thoracotomy (AT). In general, patients QoL subscales improved after surgery. After VATS, pain (3 MPO P=0.012), dyspnoea (1 MPO P=0.030) and thoracic pain (1 MPO P=0.038) decreased significantly. After AT, a significant increase was seen in general QoL (1 MPO P=0.036, 3 MPO P=0.034, 12 MPO P=0.025), physical (6 MPO P=0.025) and emotional functioning (12 MPO P=0.017). Dyspnoea (12 MPO P=0.042) and coughing (6 MPO P=0.046) decreased after AT. After surgery, AT and VATS are comparable in QoL evolution with the exception of a significant difference at 1 MPO in physical, role and cognitive functioning (P=0.002, P=0.002 and P=0.0018, respectively) and dyspnoea (P=0.041) in favour of VATS. Comparing VATS and AT in QoL evolution, significant differences are seen in thoracic pain evolution in favour of VATS (6 MPO P=0.037). After surgery, AT and VATS are comparable in QoL subscales with exception of a significant difference at 1 MPO in favour of VATS. Dyspnoea and coughing improved after surgery.

Entities:  

Mesh:

Year:  2007        PMID: 17704125     DOI: 10.1510/icvts.2007.159939

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  A modified two-port thoracoscopic technique versus axillary minithoracotomy for the treatment of recurrent spontaneous pneumothorax: a prospective randomized study.

Authors:  Christophoros N Foroulis; Kyriakos Anastasiadis; Nicholas Charokopos; Polychronis Antonitsis; Polychronis Antonitisis; Homerus V Halvatzoulis; George T Karapanagiotidis; Vassilis Grosomanidis; Christos Papakonstantinou
Journal:  Surg Endosc       Date:  2011-05-12       Impact factor: 4.584

Review 2.  Video-assisted thoracic surgery for pneumothorax: republication of a systematic review and a proposal by the guideline committee of the Japanese association for chest surgery 2014.

Authors:  Taichiro Goto; Yoshihisa Kadota; Takeshi Mori; Shin-ichi Yamashita; Hirotoshi Horio; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-09-04

Review 3.  Minimally invasive procedures.

Authors:  Nikolaos Baltayiannis; Chandrinos Michail; George Lazaridis; Dimitrios Anagnostopoulos; Sofia Baka; Ioannis Mpoukovinas; Vasilis Karavasilis; Sofia Lampaki; Antonis Papaiwannou; Anastasia Karavergou; Ioannis Kioumis; Georgia Pitsiou; Nikolaos Katsikogiannis; Kosmas Tsakiridis; Aggeliki Rapti; Georgia Trakada; Athanasios Zissimopoulos; Konstantinos Zarogoulidis; Paul Zarogoulidis
Journal:  Ann Transl Med       Date:  2015-03

4.  Videothoracoscopic surgical approach for spontaneous pneumothorax: review of the pertinent literature.

Authors:  Hiroyuki Sakurai
Journal:  World J Emerg Surg       Date:  2008-07-21       Impact factor: 5.469

5.  The usefulness of two-port video-assisted thoracosopic surgery in low-risk patients with secondary spontaneous pneumothorax compared with open thoracotomy.

Authors:  Kyoung Taek Park
Journal:  Ann Thorac Med       Date:  2014-01       Impact factor: 2.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.